BioAmber (BIOA) is Initiated by Rodman & Renshaw to Buy, Price Target at $18

BioAmber (BIOA) is Initiated by Rodman & Renshaw to Buy according to the research report released to the investors. The brokerage firm has set the Price Target of the shares at $18. The shares recommendation by the Brokerage Firm was released on Jan-5-2016.

BioAmber Inc. is up 20.47% in the last 3-month period. Year-to-Date the stock performance stands at -26.34%.

BioAmber Inc. (NYSE:BIOA) has lost 13.81% during the past week and dropped 20.26% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 13.09%. BioAmber Inc. (NYSE:BIOA) has underperformed the index by 18.4% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

Shares of BioAmber Inc. (NYSE:BIOA) ended Thursday session in red amid volatile trading. The shares closed down 0.49 points or 7.35% at $6.18 with 68,602 shares getting traded. Post opening the session at $6.72, the shares hit an intraday low of $6.06 and an intraday high of $6.72 and the price vacillated in this range throughout the day. The company has a market cap of $160 million and the number of outstanding shares have been calculated to be 25,857,671 shares. The 52-week high of BioAmber Inc. (NYSE:BIOA) is $11.3 and the 52-week low is $4.639.

Currently the company Insiders own 7.83% of BioAmber Inc. shares according to the proxy statements. Institutional Investors own 41.99% of BioAmber Inc. shares. During last six month period, the net percent change held by insiders has seen a change of 54.73%. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, Hartmann Michael A., officer (Executive Vice President) of Bioamber Inc., unloaded 21,477 shares at an average price of $8.11 on December 3, 2015. The total amount of the transaction was worth $174,178, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

BioAmber Inc. (BioAmber) is a chemical company. The Company manufactures its bio-succinic acid in a facility using a commercial scale 350,000 liter fermenter in Pomacle, France. During the year ended December 31, 2011, the Company produced 487,000 pounds, or 221 metric tons, of bio-succinic acid at this facility. Succinic acid is used to manufacture a range of products used every day, including plastics, food additives and personal care products, and can also be used as a building block for a range of derivative chemicals. The Company produces and sells bio-succinic acid using its process for petroleum-derived succinic acid. It also has additional bio-based products under development with partners including bio-succinic acid derivatives, such as BDO, and applications of bio-succinic acid, such as plasticizers, polyurethanes and de-icing solutions. During 2011, the Company created a wholly owned subsidiary, BioAmber International, S.a.r.l.